Petter S. Woll, PhD

Therapeutic targeting of cancer stem cells in mouse and human myelodysplastic syndromes

Myelodysplastic syndromes is a hematologic malignancy driven by rare cancer stem cells defective in their ability to generate mature blood cells. Our goal is to identify drugable targets that can restore the cancer stem cells’ ability to generate functionally normal blood cells, thereby hopefully eliminating the malignant features of these cells.